Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel - 18/04/17
Doi : 10.1016/j.jaci.2016.10.010
Alkis Togias, MD a, Susan F. Cooper, MSc a, ⁎ 
, Maria L. Acebal, JD b, Amal Assa'ad, MD c, James R. Baker, MD d, Lisa A. Beck, MD e, Julie Block f, Carol Byrd-Bredbenner, PhD, RD, FAND g, Edmond S. Chan, MD, FRCPC h, Lawrence F. Eichenfield, MD i, David M. Fleischer, MD j, George J. Fuchs, MD k, Glenn T. Furuta, MD l, Matthew J. Greenhawt, MD, MBA, MSc j, Ruchi S. Gupta, MD, MPH m, Michele Habich, DNP, APN/CNS, CPN n, Stacie M. Jones, MD o, Kari Keaton p, Antonella Muraro, MD, PhD q, Marshall Plaut, MD a, Lanny J. Rosenwasser, MD r, Daniel Rotrosen, MD a, Hugh A. Sampson, MD s, Lynda C. Schneider, MD t, Scott H. Sicherer, MD u, Robert Sidbury, MD, MPH v, Jonathan Spergel, MD, PhD w, David R. Stukus, MD x, Carina Venter, PhD, RD y, Joshua A. Boyce, MD z
, Maria L. Acebal, JD b, Amal Assa'ad, MD c, James R. Baker, MD d, Lisa A. Beck, MD e, Julie Block f, Carol Byrd-Bredbenner, PhD, RD, FAND g, Edmond S. Chan, MD, FRCPC h, Lawrence F. Eichenfield, MD i, David M. Fleischer, MD j, George J. Fuchs, MD k, Glenn T. Furuta, MD l, Matthew J. Greenhawt, MD, MBA, MSc j, Ruchi S. Gupta, MD, MPH m, Michele Habich, DNP, APN/CNS, CPN n, Stacie M. Jones, MD o, Kari Keaton p, Antonella Muraro, MD, PhD q, Marshall Plaut, MD a, Lanny J. Rosenwasser, MD r, Daniel Rotrosen, MD a, Hugh A. Sampson, MD s, Lynda C. Schneider, MD t, Scott H. Sicherer, MD u, Robert Sidbury, MD, MPH v, Jonathan Spergel, MD, PhD w, David R. Stukus, MD x, Carina Venter, PhD, RD y, Joshua A. Boyce, MD z a National Institute of Allergy and Infectious Diseases, Bethesda, Md
b Board of Directors, Food Allergy Research & Education, McLean, Va
c Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio
d Food Allergy Research & Education, McLean, and the Division of Allergy and Clinical Immunology, University of Michigan Health System, Ann Arbor, Mich
e Department of Dermatology, University of Rochester Medical Center, NY
f National Eczema Association, San Rafael, Calif
g Department of Nutritional Sciences, Rutgers University, New Brunswick, NJ
h Division of Allergy and Immunology, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
i Departments of Dermatology and Pediatrics, University of California, San Diego School of Medicine, Rady Children's Hospital, San Diego, Calif
j Section of Allergy and Immunology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado Denver School of Medicine, Aurora, Colo
k Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Kentucky College of Medicine, Kentucky Children's Hospital, Lexington, Ky
l Digestive Health Institute, Children's Hospital Colorado, Aurora, and the Section of Pediatric Gastroenterology, University of Colorado Denver School of Medicine, Aurora, Colo
m Division of Academic General Pediatrics and Primary Care, Department of Pediatrics, and the Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Ill
n Northwestern Medicine, Central DuPage Hospital, Winfield, Ill
o Division of Allergy and Immunology, Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Ark
p Metro DC Food Allergy Support Group, Rockville, Md
q Food Allergy Referral Centre, Department of Women and Child Health, Padua University Hospital, Padua, Italy
r University of Missouri-Kansas City School of Medicine, Kansas City, Mo
s Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY
u Division of Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY
t Division of Allergy and Immunology, Boston Children's Hospital, Boston, Mass
v Department of Pediatrics, Division of Dermatology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Wash
w Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pa
x Department of Pediatrics, Section of Allergy and Immunology, Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus, Ohio
y Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
z Departments of Medicine and Pediatrics, Harvard Medical School, Boston, Mass
∗Corresponding author: Susan F. Cooper, MSc, Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 7C28, Rockville, Md 20892.Division of Allergy, Immunology, and TransplantationNational Institute of Allergy and Infectious DiseasesNational Institutes of Health5601 Fishers Lane, Room 7C28RockvilleMd20892
Abstract |
Background |
Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy.
Objectives |
Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address the prevention of peanut allergy.
Results |
The addendum provides 3 separate guidelines for infants at various risk levels for the development of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food challenges), and the timing and approaches for introduction of peanut-containing foods in the health care provider's office or at home. The addendum guidelines provide the background, rationale, and strength of evidence for each recommendation.
Conclusions |
Guidelines have been developed for early introduction of peanut-containing foods into the diets of infants at various risk levels for peanut allergy.
Le texte complet de cet article est disponible en PDF.Key words : Food, peanut, allergy, prevention, guidelines
Abbreviations used : CC, EP, GRADE, LEAP, NIAID, OFC, sIgE, SPT
Plan
| Published on behalf of the American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma & Immunology; Canadian Society of Allergy and Clinical Immunology; Society for Pediatric Dermatology; World Allergy Organization; and Society of Pediatric Nurses. Copublished in the Journal of Allergy and Clinical Immunology; Annals of Allergy, Asthma & Immunology; Allergy, Asthma & Clinical Immunology; World Allergy Organization Journal; Pediatric Dermatology; and the Journal of Pediatric Nursing. |
|
| Disclosure of potential conflict of interest: A. Assa'ad received travel support from the American College of Allergy, Asthma & Immunology (ACAAI); was an elected member of the Board of Directors for the American Academy of Allergy, Asthma, & Immunology (AAAAI) from March 2012 to March 2016; has consultant arrangements with Aimmune; is employed by Cincinnati Children's Hospital Medical Center; has received grants from DBV Technologies, Aimmune, Stanford Foundation, TEVA Pharmaceuticals, GlaxoSmithKline, the National Institutes of Health (NIH), Astellas, and Food Allergy Research & Education (FARE); and has received payment for lectures from the ACAAI. C. Byrd-Bredbenner and G. J. Fuchs III have received travel support from the NIH/National Institute of Allergy and Infectious Disease (NIAID). E. S. Chan has received travel support from the NIAID, has received grants from DBV Technologies, and has received payment for lectures from Pfizer, Sanofi, Mead Johnson, and Nestle. D. M. Fleischer has received travel support from the NIAID; is a board member for the National Peanut Board, the FAACT Medical Advisory Board, and the FARE Medical Advisory Board; has consultant arrangements with Adamis Pharmaceuticals Corporation, INSYS Therapeutics, DBV Technologies, Aimmune Therapeutics, Intrommune Therapeutics, and Kaleo Pharma; is employed by University Physicians; has received grants from Monsanto Company, Nestle Nutrition Institute, DBV Technologies, and Aimmune Therapeutics; has received payment for lectures from Nestle Nutrition Institute; and has received royalties from UpToDate. M. J. Greenhawt has received a grant from the Agency for Healthcare Research and Quality (1K08HS024599-01, Career Development Award); has received travel support from the NIAID and the Joint Taskforce on Allergy Practice Parameters; has a board membership with the National Peanut Board; has consultant arrangements with Adamis Pharmaceuticals, the Canadian Transportation Agency, Nutricia, Nestle/Gerber, Aimmune, Kaleo Pharmaceutical, and Monsanto; is an Associate Editor for the Annals of Allergy, Asthma, and Immunology; has received payment for lectures from the ACAAI, Reach MD, Thermo Fisher Scientific, the California Society for Allergy and Immunology, the Allergy and Asthma Network, the New England Society for Allergy, UCLA/Harbor Heiner Lectureship, Medscape, the Western Michigan School of Medicine, the Canadian Society of Allergy and Clinical Immunology, and the Pennsylvania Society for Allergy and Immunology. R. S. Gupta has consultant arrangements with BEFORE Brands and DBV Technologies; has received grants from the NIH, FARE, and Mylan LLC; has received payment for lectures from Grand Rounds; and has received royalties from Createspace Independent Publishing Platform. S. M. Jones is on the Research Advisory Board for FARE; is on the Scientific Advisory Board for Aimmune; has consultant arrangements with Stallergenes; has received grants from the NIH/NIAID (Consortium of Food Allergy Research and Immune Tolerance Network–IMPACT Trial), FARE, Aimmune Technologies, DBV Technologies, and the National Peanut Board; has received payment for lectures from the Kansas City Allergy Society, Mercy Children's Hospital, Riley Children's Hospital, Southwester Medical School–Children's Medical Center, the European Academy of Allergy & Clinical Immunology, the New York Allergy & Asthma Society, the University of Iowa Paul M. Seebohm Lectureship in Allergy, and the Iowa Society of Allergy, Asthma, and Immunology. A. Muraro has consultant arrangements with Meda, Novartis, and Menarini; is employed by Padua University Hospital; and has received payment for lectures from Meda and Menarini. L. J. Rosenwasser is a board member for the World Allergy Organization. H. A. Sampson has consultant arrangements with Allertein Therapeutics, Genentech/Roche, Sanofi, Stallergenes, Danone, and Merck; is employed part time as Chief Scientific Officer for DBV Technologies; has received grants from the NIAID and the Immune Tolerance Network; has received royalties from UpToDate and Elsevier; has been offered stock options in DBV Technologies; and is chairman of PhARF Award Selection Committee for Thermo Fisher. L. C. Schneider is on the Medical Advisory Board for FARE, has received a grant from DBV Technologies, and has received stock/stock options in Antera Therapeutics. S. H. Sicherer has received grants from the NIAID, FARE, and HAL Allergy; has received royalties from UpToDate; and is serving as Associate Editor for the Journal of Allergy and Clinical Immunology: In Practice. R. Sidbury has received travel support from the NIH and the Hawaii Dermatology Seminar, has consultant arrangements with Anacor, has provided expert witness testimony on behalf of Roche in Accutane–inflammatory bowel disease cases, has received a grant from Epidermolysis Bullosa Research Partnership, has received payment for lectures from the Taiwanese Dermatological Society, and has received royalties from UpToDate. J. Spergel has consultant arrangements with DBV Technologies and Danone; has received grants from DBV Technologies, Aimmune Therapeutics, and the NIH; has received payment for lectures for Dartmouth College, the ACAAI, and the Florida Allergy Society; and has received stock/stock options in DBV Technologies. D. R. Stukus has received payment for lectures from the ACAAI. C. Venter has consultant arrangements with Danone and Nestle, has received payment for lectures from Mead Johnson, and has received travel support from Thermo Fisher. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
Publié par Elsevier Masson SAS.
Vol 139 - N° 1
P. 29-44 - janvier 2017 Retour au numéro
Article précédent
- Clinical potential for imaging in patients with asthma and other lung disorders
- Emily M. DeBoer, David R. Spielberg, Alan S. Brody
- The Editors' Choice
- Cezmi A. Akdis, Zuhair K. Ballas, the Associate Editors of the JACI
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?